GC Cell "ImmunCell-LC Injection RWD Study, Abstract Accepted at European Conference"

GC Cell announced on the 5th that the real-world data (RWD) study results of Immuncell-LC, an anti-cancer immune cell therapy, have been accepted as an abstract at the European Society of Surgical Oncology (ESSO) conference. ESSO2024 is scheduled to be held in Belgium from October 2 to 4.

European Society of Surgical Oncology (ESSO) logo

The company explained that the acceptance of the ESSO abstract is significant as it analyzed patient groups showing clinically meaningful improvements and various combination options through RWD related to the combined administration of Immuncell-LC, following the abstract presentation at the American Association for Cancer Research (AACR) in April. In particular, it provides important evidence for future indication expansion strategies and allows sharing and recognition with leading international surgical oncology experts.

A GC Cell representative stated, "Based on the accumulated real-world data (RWD) results of Immuncell-LC, we are also reviewing basic research on combination therapies with immune checkpoint inhibitors such as programmed cell death protein (PD)-(L)1."